Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: The results from the REDUCE study

Japanese Journal of Clinical Oncology

Volumn 41, Issue 3, 2011, Pages 417-423

  Akaza, Hideyuki ^a   Kanetake, Hiroshi ^b   Tsukamoto, Taiji ^c   Miyanaga, Naoto ^a   Sakai, Hideki ^b   Masumori, Naoya ^c   Nakatsu, Hiroomi ^d   Sagiyama, Kazuyuki ^e   Sakamoto, Sadaaki ^f   Endo, Yukihiro ^g   Yamanouchi, Takayoshi ^g  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d ASAHI GENERAL HOSPITAL   (Japan)

^e Sagiyama Urology Clinic   (Japan)

^f Nakamura Hospital   (Japan)

^g Development and Medical Affairs Division   (Japan)

Author keywords

Asian; Dutasteride; Japanese; Prostate cancer; REDUCE

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ACINAR CELL; ADULT; AGED; ARTICLE; ASIAN; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; GLEASON SCORE; HUMAN; JAPANESE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; POST HOC ANALYSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

5-ALPHA REDUCTASE INHIBITORS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; AZASTEROIDS; DOUBLE-BLIND METHOD; HUMANS; INTERNATIONAL AGENCIES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PLACEBOS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RISK REDUCTION BEHAVIOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79952387955     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq221     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. American Cancer Society. Cancer Facts & Figures, 2009. Atlanta. 2009 (cited 6 May 2010). http://www.cancer.org/downloads/STT/500809web.pdf.
3. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005;41:834-45.
4. Crawford ED, Andriole GL, Marberger M, Rittmaster RS. Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology 2010;75:502-9.
5. Rittmaster RS, Fleshner NE, Thompson IM. Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol 2009;55:1064-73.
6. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
7. Serfling R, Shulman M, Thompson GL, Xiao Z, Benaim E, Roehrborn CG, et al. Quantifying the impact of prostate volumes, number of biopsy cores and 5 alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling. J Urol 2007;177:2352-6.
8. Briganti A, Chun FK, Suardi N, Gallina A, Walz J, Graefen M, et al. Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer 2007;43:2669-77.
9. Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 2005;23:7546-54.
10. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128-33.
11. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-83.
12. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, et al. Use of 5 alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol 2009;181:1642-57.
13. Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2007;10:149-54.
14. Thomas LN, Douglas RC, Lazier CB, Too CKL, Rittmaster RS, Tindall DJ. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 2008;53:244-52.
15. Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004;64:537-41.
16. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
17. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, et al. Chemoprevention of prostate cancer in men at highrisk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172:1314-7.
18. Chung BH, Roehrborn CG, Siami P, Major-Walker K, Morrill BB, Wilson TH, et al. Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. Prostate Cancer Prostatic Dis 2009;12:152-9.
19. Tsukamoto T, Endo Y, Narita M. Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia. Int J Urol 2009;16:745-50.
20. Masumori N, Tsukamoto T, Kumamoto Y, Miyake H, Rhodes T, Girman CJ, et al. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. J Urol 1996;155:1324-7.
21. Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, Masumori N, et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 1995;75:347-53.
22. Jin B, Turner L, Zhou Z, Zhou EL, Handelsman DJ. Ethnicity and migration as determinants of human prostate size. J Clin Endocrinol Metab 1999;84:3613-9.
23. Gupta A, Aragaki C, Gotoh M, Masumori N, Ohshima S, Tsukamoto T, et al. Relationship between prostate specific antigen and indexes of prostate volume in Japanese men. J Urol 2005;173:503-6.
24. Chang YL, Lin AT, Chen KK, Chang YH, Wu HHH, Kuo JY, et al. Correlation between serum prostate specific antigen and prostate volume in Taiwanese men with biopsy proven benign prostatic hyperplasia. J Urol 2006;176:196-9.
25. Ito K, Raaijmakers R, Roobol M, Wildhagen M, Yamanaka H, Schröder FH. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening. Cancer 2005;103:242-50.
26. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
27. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010;28:1117-23.
28. Shao YH, Albertsen PC, Roberts CB, Lin Y, Mehta AR, Stein MN, et al. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/mL. Arch Intern Med 2010;170:1256-61.
29. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005;12:46-61.